论文部分内容阅读
目的探讨糖类抗原CA125、癌胚抗原CEA、人附睾蛋白HE4联合测定卵巢癌的临床价值。方法CA125、CEA用日本全自动AIA-360磁珠法电化学发光免疫检测及其配套试剂。HE4采用ELISA法,试剂盒由上海研吉生物科技有限公司提供,仪器为雷杜RT-2100C型酶标仪(450nm)。结果卵巢癌患者CA125、CEA、HE4阳性率均高于健康成人组,差异有统计学意义(P<0.05)。CA125、CEA、HE4阳性率在卵巢癌组与良性包块组、对照组之间存在显著差异(P<0.05、P>0.01)。结论三项指标联合可提高卵巢癌诊断的阳性率。
Objective To investigate the clinical value of carbohydrate antigen CA125, carcinoembryonic antigen CEA and human epididymal protein HE4 in the diagnosis of ovarian cancer. Methods CA125, CEA with Japan automatic AIA-360 magnetic bead method of electrochemical luminescence immunoassay and reagents. HE4 using ELISA method, the kit provided by the Shanghai Institute of Biotechnology Co., Ltd., Lei Du RT-2100C microplate reader (450nm). Results The positive rates of CA125, CEA and HE4 in patients with ovarian cancer were significantly higher than those in healthy adults (P <0.05). The positive rates of CA125, CEA and HE4 were significantly different between ovarian cancer group and benign masses and the control group (P <0.05, P> 0.01). Conclusion The combination of three indicators can improve the positive rate of ovarian cancer diagnosis.